A consulting-grade pharmaceutical intelligence platform with 100,000+ drug records, 19 interactive analytics dashboards, and AI-powered insights across the entire drug development lifecycle — from pipeline tracking to patent cliffs, regulatory landscape, and white space identification.
Our drug database is a comprehensive pharmaceutical intelligence platform that goes far beyond a simple searchable list. It powers 19 specialized analytics dashboards, each designed to answer specific strategic questions across the drug development lifecycle — from competitive landscape analysis to white space identification and AI-powered executive reporting.
Comprehensive global pharmaceutical database covering FDA-approved, EMA-approved, and pipeline drugs across 190+ markets.
Filter by drug name, brand, molecule, generic name, company, therapy area, disease, mechanism, target, drug class, phase, regulatory status, country, biomarker, and more.
Multi-dimensional filtering with real-time search across all key fields. Save and share filtered views with your team.
Export filtered drug records to Excel or CSV for offline analysis, reporting, and integration with your internal tools.
Built-in duplicate detection and management system that identifies and helps remove redundant records based on composite key matching.
Custom field enrichment with FDA-specific data including approval dates, application numbers, and regulatory identifiers.
RESTful analytics API with 19 intelligence modules, returning structured JSON for integration with your workflows and dashboards.
7 AI-powered analytics modules including drug similarity, portfolio benchmarking, forecasting, gap analysis, licensing radar, and executive reporting.
Each module is a purpose-built analytics dashboard with interactive charts, tables, and AI-powered insights. Filter by therapy area, company, country, phase, mechanism, or target to drill down into specific segments.
Bird's-eye view of the global pharmaceutical landscape with KPIs for approved drugs, pipeline counts, new FDA/EMA approvals, patent expiries, orphan drugs, advanced therapies, biosimilars, market concentration (HHI), and data quality metrics.
Per-company breakdown of marketed drugs, pipeline assets, therapy area focus, mechanism of action, and patent cliff exposure. Market share analysis with Herfindahl-Hirschman Index (HHI) for competitive landscape assessment.
Deep dive into each therapeutic area with approved drug counts, pipeline by phase (I–III + Registration), top companies, mechanisms, targets, biomarkers, and recent launch activity.
Mechanism of Action intelligence with per-mechanism drug counts, approved vs. pipeline split, associated companies, and disease indications. Identify which mechanisms are crowded vs. emerging.
Drug target analysis with per-target drug counts, approval status, pipeline activity, and company landscape. Identify validated vs. emerging targets and competitive intensity.
Biomarker landscape analysis with per-biomarker drug counts, approval status, pipeline activity, associated companies, and disease indications. Track precision medicine trends.
Interactive Sankey diagram showing drug development flow from Early Phase I through Phase IV and Approval. Funnel analysis with attrition rates by phase and pipeline progression percentages.
Patent expiry timeline by year, top blockbuster loss-of-exclusivity (LOE) opportunities, and company exposure to patent cliffs. Identify generics and biosimilar opportunities.
FDA and EMA approval counts, approval trends by year, regulatory status distribution, license types, licensure status, and route of administration breakdown.
Country-level analysis with approved drug counts, pipeline activity, and top companies per market. Understand geographic drug distribution and market presence.
Disease-level opportunity scoring based on approved drugs, pipeline activity, company count, and advanced therapy presence. Identifies high-opportunity disease areas.
Identifies underserved disease areas with few approved drugs but pipeline activity — representing high unmet need and innovation white space. Advanced therapy (ATMP) gap analysis included.
AI-powered drug similarity search to find structurally or mechanistically similar drugs. Useful for drug repurposing, biosimilar tracking, and competitive positioning.
Compare two companies side-by-side across portfolio size, pipeline depth, therapy area focus, mechanism diversity, and patent exposure. AI-generated competitive assessments.
AI-powered pharmaceutical market forecasting using historical approval trends, pipeline progression rates, and patent expiry data to project future market dynamics.
AI-powered analysis to identify gaps in a company's drug portfolio — missing therapy areas, underrepresented mechanisms, and untapped target opportunities.
AI-powered licensing opportunity identification — detect drugs with approaching patent expiries, pipeline assets seeking partners, and in-licensing/out-licensing opportunities.
Track the full lifecycle of drugs from discovery through approval, launch, patent expiry, and loss of exclusivity. Lifecycle stage distribution and timeline analysis.
Generate comprehensive AI-powered executive reports summarizing the entire analytics dashboard — key findings, strategic insights, and actionable recommendations.
Every drug record in our database contains up to 40+ structured fields, enabling precise filtering, cross-referencing, and multi-dimensional analysis.
Search 100K+ drug records with 40+ filter dimensions. Find exactly the drugs, companies, or therapy areas you need.
Switch between 19 analytics dashboards with interactive charts, Sankey diagrams, tables, and funnel analysis.
Leverage 7 AI modules for drug similarity, benchmarking, forecasting, gap analysis, licensing radar, and executive reports.
Export to Excel/CSV, generate AI executive reports, and turn intelligence into confident strategic decisions.
Track competitor pipelines, monitor patent cliffs, and benchmark portfolios against rivals.
Identify in-licensing opportunities, detect drugs approaching LOE, and find pipeline assets seeking partners.
Identify therapy area gaps, assess white space, and prioritize pipeline investments.
Monitor FDA/EMA approval trends, track regulatory statuses, and forecast approval timelines.
Analyze geographic drug distribution, track launch years, and assess market opportunity by disease.
Explore MoA landscapes, identify emerging targets, and find drug repurposing opportunities.
Access 100,000+ drug records and 19 analytics dashboards today. No registration required to browse — sign up to save filters and export data.
Want a guided demo? Contact our team to schedule a walkthrough.